All In Biotech

Drug Trial Radar · NCT06551506

The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products

A Prospective, Randomized, Open-label Phase 4 Study of the Immunology and Safety of Maternal RSV Vaccination (ABRYSVO (TM)), Infant Nirsevimab (BEYFORTUS (TM)) Immunization, or Both Products During the First Year of Life

Last checked: Nov 20, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 181 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

181

Actual

Start

Sep 19, 2024

Primary completion

May 5, 2026

Study completion May 5, 2026

Sponsor

Sponsor type
NIH
First posted
Aug 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Respiratory Syncytial Virus (RSV) is the leading cause of lower respiratory tract infections (LRTIs) in infants and young children. It is also a leading cause of mortality in children \<5 years of age worldwide. Until recently, no Food and Drug Administration (FDA)-approved vaccines were available to prevent RSV infection. The only prophylactic product for RSV prevention recommended for infants was the monoclonal antibody palivizumab, but administration was limited to those with extreme prematurity, chronic lung disease, or hemodynamically significant congenital heart disease. However, in 2023, the FDA approved two products designed to prevent RSV lower respiratory tract disease (LRTD) in all infants: an active RSV vaccine based on the prefusion F protein (RSVpreF, ABRYSVO, Pfizer) administered during pregnancy, and a passive, long-acting monoclonal antibody (nirsevimab-alip \[henceforth referred to as nirsevimab\], BEYFORTUS, AstraZeneca) administered to infants at birth or at the start of their first RSV season. Both products were evaluated in Phase 3 pivotal clinical trials and have high efficacy in preventing LRTD caused by RSV in infants. Although there is no established correlate of protection against RSV, antibodies have been associated with protection across multiple studies. The clinical development plan for the products did not include comprehensive evaluations of the magnitude and durability of the immune response, nor were the two products tested in a single trial. This study is a prospective, randomized, open-label Phase 4 study with the primary objective of evaluating the magnitude and durability of RSV-specific neutralizing antibodies in infants through 12 months of life following either maternal RSV vaccination, infant nirsevimab administration, or both products combined.

Conditions

  • Respiratory Syncytial Virus Infection

Interventions

  • AbrysvoBiological

    A maternal RSV vaccine based on the prefusion F protein administered during pregnancy

  • BeyfortusBiological

    A passive, long-acting monoclonal antibody to Respiratory syncytial virus (RSV) administered to infants

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric mean titer (GMT) of serum RSV A and B neutralizing antibodies in infantsTime frame: Through Day 366

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Emory University School of Medicine

    Atlanta, Georgia

  • University of Maryland, School of Medicine, Center for Vaccine Development and Global Health

    Baltimore, Maryland

  • New York University School of Medicine - Langone Medical Center - Vaccine Center

    New York, New York

  • University of Rochester Medical Center - Vaccine Research Unit

    Rochester, New York

  • Cincinnati Children's Hospital Medical Center Vaccine Research Center

    Cincinnati, Ohio

  • University of Pittsburgh - Medicine - Infectious Diseases

    Pittsburgh, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor College of Medicine

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.